Selected research
Industry Research
Islet Amyloid Polypeptide Industry Research Report 2026
Market perspective
The global Islet Amyloid Polypeptide market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Islet Amyloid Polypeptide is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Islet Amyloid Polypeptide is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Islet Amyloid Polypeptide is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Islet Amyloid Polypeptide include Adocia SAS, Neurimmune Holding AG, Nordic Bioscience A/S, Prothena Corp Plc, reMYND NV, Zealand Pharma AS, AstraZeneca Plc and Eli Lilly and Co, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Islet Amyloid Polypeptide market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Islet Amyloid Polypeptide Market by Company
Adocia SAS
Neurimmune Holding AG
Nordic Bioscience A/S
Prothena Corp Plc
reMYND NV
Zealand Pharma AS
AstraZeneca Plc
Eli Lilly and Co
Islet Amyloid Polypeptide Segment by Type
KBP-088
KBP-056
DACRA-089
DACRA-042
AC-253
Others
Islet Amyloid Polypeptide Segment by Application
Gastrointestinal
Musculoskeletal Disorders
Metabolic Disorders
Others
Islet Amyloid Polypeptide Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Islet Amyloid Polypeptide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Islet Amyloid Polypeptide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Islet Amyloid Polypeptide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Islet Amyloid Polypeptide manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Islet Amyloid Polypeptide by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Islet Amyloid Polypeptide in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- KBP-088
- KBP-056
- DACRA-089
- DACRA-042
- AC-253
- Others
Applications
- Gastrointestinal
- Musculoskeletal Disorders
- Metabolic Disorders
- Others
Companies covered
- Adocia SAS
- Neurimmune Holding AG
- Nordic Bioscience A/S
- Prothena Corp Plc
- reMYND NV
- Zealand Pharma AS
- AstraZeneca Plc
- Eli Lilly and Co
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Islet Amyloid Polypeptide Market Size (2021-2032)
- 2.2.2 Global Islet Amyloid Polypeptide Sales (2021-2032)
- 2.2.3 Global Islet Amyloid Polypeptide Market Average Price (2021-2032)
- 2.3 Islet Amyloid Polypeptide by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 KBP-088
- 2.3.3 KBP-056
- 2.3.4 DACRA-089
- 2.3.5 DACRA-042
- 2.3.6 AC-253
- 2.3.7 Others
- 2.4 Islet Amyloid Polypeptide by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Gastrointestinal
- 2.4.3 Musculoskeletal Disorders
- 2.4.4 Metabolic Disorders
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Islet Amyloid Polypeptide Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Islet Amyloid Polypeptide Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Islet Amyloid Polypeptide Revenue of Manufacturers (2021-2026)
- 3.4 Global Islet Amyloid Polypeptide Average Price by Manufacturers (2021-2026)
- 3.5 Global Islet Amyloid Polypeptide Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Islet Amyloid Polypeptide, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Islet Amyloid Polypeptide, Product Type & Application
- 3.8 Global Manufacturers of Islet Amyloid Polypeptide, Established Date
- 3.9 Global Islet Amyloid Polypeptide Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Adocia SAS
- 4.1.1 Adocia SAS Company Information
- 4.1.2 Adocia SAS Business Overview
- 4.1.3 Adocia SAS Islet Amyloid Polypeptide Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Adocia SAS Islet Amyloid Polypeptide Product Portfolio
- 4.1.5 Adocia SAS Recent Developments
- 4.2 Neurimmune Holding AG
- 4.2.1 Neurimmune Holding AG Company Information
- 4.2.2 Neurimmune Holding AG Business Overview
- 4.2.3 Neurimmune Holding AG Islet Amyloid Polypeptide Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Neurimmune Holding AG Islet Amyloid Polypeptide Product Portfolio
- 4.2.5 Neurimmune Holding AG Recent Developments
- 4.3 Nordic Bioscience A/S
- 4.3.1 Nordic Bioscience A/S Company Information
- 4.3.2 Nordic Bioscience A/S Business Overview
- 4.3.3 Nordic Bioscience A/S Islet Amyloid Polypeptide Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Nordic Bioscience A/S Islet Amyloid Polypeptide Product Portfolio
- 4.3.5 Nordic Bioscience A/S Recent Developments
- 4.4 Prothena Corp Plc
- 4.4.1 Prothena Corp Plc Company Information
- 4.4.2 Prothena Corp Plc Business Overview
- 4.4.3 Prothena Corp Plc Islet Amyloid Polypeptide Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Prothena Corp Plc Islet Amyloid Polypeptide Product Portfolio
- 4.4.5 Prothena Corp Plc Recent Developments
- 4.5 reMYND NV
- 4.5.1 reMYND NV Company Information
- 4.5.2 reMYND NV Business Overview
- 4.5.3 reMYND NV Islet Amyloid Polypeptide Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 reMYND NV Islet Amyloid Polypeptide Product Portfolio
- 4.5.5 reMYND NV Recent Developments
- 4.6 Zealand Pharma AS
- 4.6.1 Zealand Pharma AS Company Information
- 4.6.2 Zealand Pharma AS Business Overview
- 4.6.3 Zealand Pharma AS Islet Amyloid Polypeptide Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Zealand Pharma AS Islet Amyloid Polypeptide Product Portfolio
- 4.6.5 Zealand Pharma AS Recent Developments
- 4.7 AstraZeneca Plc
- 4.7.1 AstraZeneca Plc Company Information
- 4.7.2 AstraZeneca Plc Business Overview
- 4.7.3 AstraZeneca Plc Islet Amyloid Polypeptide Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 AstraZeneca Plc Islet Amyloid Polypeptide Product Portfolio
- 4.7.5 AstraZeneca Plc Recent Developments
- 4.8 Eli Lilly and Co
- 4.8.1 Eli Lilly and Co Company Information
- 4.8.2 Eli Lilly and Co Business Overview
- 4.8.3 Eli Lilly and Co Islet Amyloid Polypeptide Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Eli Lilly and Co Islet Amyloid Polypeptide Product Portfolio
- 4.8.5 Eli Lilly and Co Recent Developments
5 Global Islet Amyloid Polypeptide Market Scenario by Region
- 5.1 Global Islet Amyloid Polypeptide Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Islet Amyloid Polypeptide Sales by Region: 2021-2032
- 5.2.1 Global Islet Amyloid Polypeptide Sales by Region: 2021-2026
- 5.2.2 Global Islet Amyloid Polypeptide Sales by Region: 2027-2032
- 5.3 Global Islet Amyloid Polypeptide Revenue by Region: 2021-2032
- 5.3.1 Global Islet Amyloid Polypeptide Revenue by Region: 2021-2026
- 5.3.2 Global Islet Amyloid Polypeptide Revenue by Region: 2027-2032
- 5.4 North America Islet Amyloid Polypeptide Market Facts & Figures by Country
- 5.4.1 North America Islet Amyloid Polypeptide Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Islet Amyloid Polypeptide Sales by Country (2021-2032)
- 5.4.3 North America Islet Amyloid Polypeptide Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Islet Amyloid Polypeptide Market Facts & Figures by Country
- 5.5.1 Europe Islet Amyloid Polypeptide Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Islet Amyloid Polypeptide Sales by Country (2021-2032)
- 5.5.3 Europe Islet Amyloid Polypeptide Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Islet Amyloid Polypeptide Market Facts & Figures by Country
- 5.6.1 Asia Pacific Islet Amyloid Polypeptide Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Islet Amyloid Polypeptide Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Islet Amyloid Polypeptide Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Islet Amyloid Polypeptide Market Facts & Figures by Country
- 5.7.1 South America Islet Amyloid Polypeptide Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Islet Amyloid Polypeptide Sales by Country (2021-2032)
- 5.7.3 South America Islet Amyloid Polypeptide Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Islet Amyloid Polypeptide Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Islet Amyloid Polypeptide Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Islet Amyloid Polypeptide Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Islet Amyloid Polypeptide Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Islet Amyloid Polypeptide Sales by Type (2021-2032)
- 6.1.1 Global Islet Amyloid Polypeptide Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Islet Amyloid Polypeptide Sales Market Share by Type (2021-2032)
- 6.2 Global Islet Amyloid Polypeptide Revenue by Type (2021-2032)
- 6.2.1 Global Islet Amyloid Polypeptide Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Islet Amyloid Polypeptide Revenue Market Share by Type (2021-2032)
- 6.3 Global Islet Amyloid Polypeptide Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Islet Amyloid Polypeptide Sales by Application (2021-2032)
- 7.1.1 Global Islet Amyloid Polypeptide Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Islet Amyloid Polypeptide Sales Market Share by Application (2021-2032)
- 7.2 Global Islet Amyloid Polypeptide Revenue by Application (2021-2032)
- 7.2.1 Global Islet Amyloid Polypeptide Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Islet Amyloid Polypeptide Revenue Market Share by Application (2021-2032)
- 7.3 Global Islet Amyloid Polypeptide Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Islet Amyloid Polypeptide Value Chain Analysis
- 8.1.1 Islet Amyloid Polypeptide Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Islet Amyloid Polypeptide Production Mode & Process
- 8.2 Islet Amyloid Polypeptide Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Islet Amyloid Polypeptide Distributors
- 8.2.3 Islet Amyloid Polypeptide Customers
9 Global Islet Amyloid Polypeptide Analyzing Market Dynamics
- 9.1 Islet Amyloid Polypeptide Industry Trends
- 9.2 Islet Amyloid Polypeptide Industry Drivers
- 9.3 Islet Amyloid Polypeptide Industry Opportunities and Challenges
- 9.4 Islet Amyloid Polypeptide Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst